Theravance Biopharma, Inc.

Theravance Biopharma is a biopharmaceutical company headquartered in South San Francisco, California, that develops and commercializes respiratory and neurological medicines. The company's marketed product is YUPELRI, a once-daily nebulized long-acting muscarinic antagonist approved for treating chronic obstructive pulmonary disease (COPD). YUPELRI is commercialized through a strategic collaboration with Viatris Inc., which handles development and commercialization responsibilities.

The company's pipeline includes Ampreloxetine, a norepinephrine reuptake inhibitor in late-stage development for symptomatic neurogenic orthostatic hypotension in patients with Multiple System Atrophy. This represents the company's expansion into neurological indications beyond its established respiratory focus.

Theravance Biopharma operates as a smaller-scale biopharmaceutical firm with 97 full-time employees and maintains operations primarily in the United States. The company was incorporated in California in 2013 and is traded on Nasdaq.